Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?

18th March 2019 Uncategorised 0

Novo Nordisk has at least four more years to build up its newer diabetes drugs before they’ll have to compete with Teva’s knockoff versions of its own blockbuster GLP-1 Victoza. And it’s hoping to get its oral semaglutide—the first GLP-1 pill—to market by year’s end.

More: Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Source: fierce